<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719797</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000598582</org_study_id>
    <secondary_id>GONO-TRIBE</secondary_id>
    <secondary_id>ASL608LIOM04</secondary_id>
    <secondary_id>EUDRACT:2008-001537-10</secondary_id>
    <nct_id>NCT00719797</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <acronym>TRIBE</acronym>
  <official_title>A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Oncologico del Nord-Ovest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Oncologico del Nord-Ovest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irinotecan, oxaliplatin, leucovorin, and
      fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the
      cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can
      block tumor growth in different ways. Some block the ability of tumor cells to grow and
      spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
      Giving combination chemotherapy together with bevacizumab may kill more tumor cells.

      PURPOSE: This randomized phase III trial is comparing two combination chemotherapy regimens
      given together with bevacizumab to see how well they work as first-line therapy in treating
      patients with metastatic colorectal cancer that cannot be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To compare the progression-free survival of bevacizumab in combination with oxaliplatin,
           irinotecan hydrochloride, fluorouracil, and leucovorin calcium (FOLFOXIRI) versus
           bevacizumab in combination with irinotecan hydrochloride, fluorouracil, and leucovorin
           calcium (FOLFIRI) in patients with unresectable, metastatic colorectal cancer.

      Secondary

        -  To evaluate the safety profile, including long-term adverse events of these regimens in
           these patients.

        -  To compare the overall response rate, duration of response, and secondary R0 surgery
           rates of metastases and overall survival between treatment arms.

        -  To evaluate potential surrogate markers predictive of bevacizumab activity.

      OUTLINE: This is a multicenter study. Patients are stratified according to ECOG performance
      status (0 vs 1-2), prior adjuvant chemotherapy (yes vs no), and participating center.
      Patients are randomized to 1 of 2 treatment arms.

        -  Arm I (FOLFOXIRI): Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin
           IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1.
           Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.

        -  Arm II (FOLFIRI): Patients receive irinotecan hydrochloride IV over 1 hour, leucovorin
           calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil
           IV continuously over 48 hours beginning on day 1.

      In both arms, treatment repeats every 2 weeks for up to 12 courses. Treatment with
      bevacizumab, fluorouracil, and leucovorin calcium continues in the absence of disease
      progression or unacceptable toxicity.

      Patients undergo serum extraction and blood sample collection periodically for genotyping
      studies. Patients also undergo collection of tumoral sections from paraffin embedded primary
      and/or metastatic lesions periodically for immunohistochemical analyses.

      After completion of study treatment, patients are followed every 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 54 months</time_frame>
    <description>To compare the progression free survival of bevacizumab in combination with oxaliplatin, irinotecan and infusional 5FU/LV (&quot;GONO&quot; FOLFOXIRI regimen) to bevacizumab in combination with irinotecan and infusional 5FU/LV (FOLFIRI regimen)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>up to 54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>up to 54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary R0 surgery rates of metastases</measure>
    <time_frame>up to 54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surrogate markers predictive of bevacizumab activity</measure>
    <time_frame>up to 54 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">509</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (FOLFOXIRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (FOLFIRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive irinotecan hydrochloride IV over 1 hour, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (FOLFOXIRI)</arm_group_label>
    <arm_group_label>Arm II (FOLFIRI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (FOLFOXIRI)</arm_group_label>
    <arm_group_label>Arm II (FOLFIRI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (FOLFOXIRI)</arm_group_label>
    <arm_group_label>Arm II (FOLFIRI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (FOLFOXIRI)</arm_group_label>
    <arm_group_label>Arm II (FOLFIRI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (FOLFOXIRI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed colorectal cancer

               -  Unresectable metastatic disease

          -  Measurable disease, defined as ≥ 1 measurable lesion according to RECIST criteria

          -  No prior chemotherapy for metastatic disease

          -  No untreated brain metastases, spinal cord compression, or primary brain tumors

          -  No history or evidence of CNS disease by physical examination unless adequately
             treated (e.g., uncontrolled seizure despite standard medical therapy or history of
             stroke)

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  ECOG performance status (PS) 0-2 (≤ 70 years of age) OR ECOG PS 0 (71-75 years of age)

          -  Life expectancy ≥ 12 weeks

          -  Neutrophils ≥ 1.5 x 10^9/L

          -  Platelet count ≥ 100 x 10^9/L

          -  Hemoglobin &gt; 9 g/dL

          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN if f liver metastases present)

          -  Alkaline phosphatase ≤ 2.5 times ULN (≤ 5 times ULN if liver metastases present)

          -  Creatinine clearance &gt; 50 mL/min OR serum creatinine ≤ 1.5 times ULN

          -  Proteinuria &lt; 2+ by dipstick OR urine protein ≤ 1 g by 24-hr urine collection

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        Exclusion criteria:

          -  Serious, nonhealing wound, ulcer, or bone fracture

          -  Evidence of bleeding diathesis or coagulopathy

          -  Uncontrolled hypertension

          -  Clinically significant (i.e., active) cardiovascular disease, including any of the
             following:

               -  Cerebrovascular accidents within the past 6 months

               -  Myocardial infarction within the past 6 months

               -  Unstable angina

               -  New York Heart Association class II-IV congestive heart failure

               -  Serious cardiac arrhythmia requiring medication

          -  Known allergy to Chinese hamster ovary cell proteins or any of the components of the
             study medications

          -  Other co-existing malignancy or malignancy diagnosed within the past 5 years, except
             for basal cell or squamous cell carcinoma, or carcinoma in situ of the cervix

          -  Symptomatic peripheral neuropathy ≥ grade 1 according to the NCI Common Toxicity
             Criteria

          -  Lack of physical integrity of the upper gastrointestinal tract

          -  Malabsorption syndrome

          -  Inability to take oral medication

          -  Significant traumatic injury within the past 28 days

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 4 weeks since prior radiotherapy

          -  More than 10 days since prior and no concurrent ongoing treatment with anticoagulants
             for therapeutic purposes

          -  More than 28 days since prior and no concurrent major surgical procedure

          -  More than 28 days since prior open biopsy

          -  More than 30 days since prior investigational agents

          -  No concurrent chronic daily high-dose acetylsalicylic acid (&gt; 325 mg/day)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfredo Falcone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Presidio Ospedaliero di Livorno</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Civile Ss. Antonio E Biagio Di Alessandria - Alessandria (Al) Oncologia Medica</name>
      <address>
        <city>Alessandria</city>
        <zip>15100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona - Ancona (An) Oncologia Medica</name>
      <address>
        <city>Ancona</city>
        <zip>60100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.O. Zona Aretina - Ospedale S. Donato Di Arezzo - Arezzo (Ar) Oncologia Medica</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Centro Di Riferimento Oncologico (Cro) - Aviano (Pn) Oncologia Medica</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Orsola F.B.F. - Brescia - Brescia (Bs) Oncologia Medica</name>
      <address>
        <city>Brescia</city>
        <zip>25122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Ospedaliero Fondazione Poliambulanza Di Brescia - Brescia (Bs) Oncologia Medica</name>
      <address>
        <city>Brescia</city>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stabilimento &quot;Perrino&quot; - Brindisi - Brindisi (Br) Oncologia Medica</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Elia - Caltanissetta (Cl) Oncologia Medica</name>
      <address>
        <city>Caltanissetta</city>
        <zip>93100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ausl 1 Di Massa E Carrara - Carrara (Ms) Oncologia Medica</name>
      <address>
        <city>Carrara</city>
        <zip>54033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cecina - Cecina (Li) Oncologia Medica</name>
      <address>
        <city>Cecina</city>
        <zip>57023</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituti Ospitalieri - Cremona - Cremona (Cr) Oncologia Medica</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Croce E Carle Di Cuneo - Cuneo (Cn) Oncoematologia</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ausl 11 Di Empoli (Fi) - Empoli (Fi) Oncologia Medica</name>
      <address>
        <city>Empoli</city>
        <zip>50053</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.S.L.N.6 -Ospedale Civile 'E.Profili'-F - Fabriano (An) Oncologia Medica</name>
      <address>
        <city>Fabriano</city>
        <zip>60044</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ausl 10 Di Firenze - Firenze (Fi) Oncologia Medica</name>
      <address>
        <city>Firenze</city>
        <zip>50122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Istituto Nazionale Per La Ricerca Sul Cancro (Ist) - Genova (Ge) Oncologia Medica</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ausl Le Di Lecce - Lecce (Le) Oncologia Medica</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aulss 21 Di Legnago (Vr) - Legnago (Vr) Oncologia Medica</name>
      <address>
        <city>Legnano</city>
        <zip>37045</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ausl 12 Di Viareggio (Lu) - Lido Di Camaiore (Lu) Oncologia Medica</name>
      <address>
        <city>Lido di Camaiore</city>
        <zip>55053</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Livorno - Livorno (Li), Oncologia Medica</name>
      <address>
        <city>Livorno</city>
        <zip>57100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Piana Di Lucca - Lucca (Lu) Oncologia Medica</name>
      <address>
        <city>Lucca</city>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Fondazione Centro S. Raffaele Del Monte Tabor - Milano (Mi) Oncologia Medica</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ca` Granda-Niguarda - Milano - Milano (Mi) Oncologia Medica</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.Gerardo - Monza - Monza (Mi) Oncologia Medica</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Federico Ii Di Napoli Oncologia Medica</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Maggiore Della Carita' Di Novara Oncologia Medica</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Di Parma Oncologia Medica</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asl 1 Di Citta' Di Castello (Pg) - Citta' Di Castello (Pg) Oncologia Medica</name>
      <address>
        <city>Perugia</city>
        <zip>06012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Di Perugia - Ospedale S. Maria Della Misericordia (Ex Silvestrini) - Perugia (Pg) Oncologia Medica</name>
      <address>
        <city>Perugia</city>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Salvatore - Pesaro (Pu) Oncologia Medica</name>
      <address>
        <city>Pesaro</city>
        <zip>61100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Della Valdinievole - Pescia (Pt) Oncologia Medica</name>
      <address>
        <city>Pescia</city>
        <zip>51017</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Piombino - Piombino (Li) Oncologia Medica</name>
      <address>
        <city>Piombino</city>
        <zip>57100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Pisana Oncologia Medica</name>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ausl 5 Di Pisa - Pisa (Pi) Oncologia Medica</name>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfredo Falcone A.O. Universitaria Pisana - Pisa (Pi) Oncologia Medica</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ausl 3 Di Pistoia - Pistoia (Pt) Oncologia Medica</name>
      <address>
        <city>Pistoia</city>
        <zip>51100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ausl 4 Di Prato - Prato (Po) Oncologia Medica</name>
      <address>
        <city>Prato</city>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Di S. Maria Nuova - Reggio Nell`Emilia (Re) Oncologia Medica</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-Medico Di Roma Oncologia Medica</name>
      <address>
        <city>Rome</city>
        <zip>00155</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I Di Roma Oncologia Medica</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Gemelli Di Roma Oncologia Medica</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Senese Oncologia Medica</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile - Sondrio - Sondrio (So) Oncologia Medica</name>
      <address>
        <city>Sondrio</city>
        <zip>23100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria S. Giovanni Battista-Molinette Di Torino Oncologia Medica</name>
      <address>
        <city>Torino</city>
        <zip>10134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2008</study_first_submitted>
  <study_first_submitted_qc>July 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2008</study_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

